U.S was Bausch Health Companies’s largest region in fiscal 2025, bringing in $6.14B of $10.27B (60%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | — | $5.19B | $5.77B | $6.14B | ||||||||||||
| U.S. & Puerto Rico | $4.84B | — | — | — | ||||||||||||
| Other | $887.00M | $1.01B | $1.08B | $1.15B | ||||||||||||
| Other Europe, Asia, The Middle East, Latin America, Africa & Other | — | — | — | — | ||||||||||||
| Segment Geographical Groups Of Countries Group One | — | — | — | — | ||||||||||||
| China | $413.00M | $441.00M | $496.00M | $493.00M | ||||||||||||
| Canada | $351.00M | $366.00M | $402.00M | $417.00M | ||||||||||||
| Ca | — | — | — | — | ||||||||||||
| Poland | $278.00M | $319.00M | $350.00M | $382.00M | ||||||||||||
| Pl | — | — | — | — | ||||||||||||
| Mexico | $276.00M | $322.00M | $315.00M | $278.00M | ||||||||||||
| Mx | — | — | — | — | ||||||||||||
| Japan | $200.00M | $194.00M | $188.00M | $192.00M | ||||||||||||
| France | $203.00M | $214.00M | $230.00M | $249.00M | ||||||||||||
| Russia | $181.00M | $148.00M | $161.00M | $198.00M | ||||||||||||
| Australia | — | — | — | — | ||||||||||||
| Au | — | — | — | — | ||||||||||||
| Germany | $147.00M | $152.00M | $159.00M | $176.00M | ||||||||||||
| Egypt | — | — | — | — | ||||||||||||
| South Korea | $77.00M | $93.00M | $146.00M | $234.00M | ||||||||||||
| Brazil | — | — | — | — | ||||||||||||
| Br | — | — | — | — | ||||||||||||
| United Kingdom | $115.00M | $125.00M | $135.00M | $141.00M | ||||||||||||
| U.K | — | — | — | — | ||||||||||||
| Spain | $84.00M | $92.00M | $99.00M | $109.00M | ||||||||||||
| Serbia | — | — | — | — | ||||||||||||
| Italy | $76.00M | $86.00M | $94.00M | $106.00M | ||||||||||||
| Segment Geographical Groups Of Countries Group Two | — | — | — | — | ||||||||||||
| Total | $8.12B | $8.76B | $9.63B | $10.27B |
Bausch Health Companies brought in $10.27B from its 14 regions in fiscal 2025, the year ended December 31, 2025. That was up 6.7% from $9.63B in fiscal 2024. U.S was the largest at $6.14B (59.8%), ahead of Other at $1.15B (11.2%) and China at $493.00M (4.8%). The other 11 regions brought in $2.48B combined.
Compared with fiscal 2024, South Korea grew fastest, up 60.3% to $234.00M, while Mexico fell the most, down 11.7% to $278.00M.
Bausch Health Companies began breaking out U.S in fiscal 2023, when it brought in $5.19B. Bausch Health Companies stopped reporting U.S. & Puerto Rico as a separate region after fiscal 2022, when it brought in $4.84B.
Bausch + Lomb was Bausch Health Companies’s largest segment in fiscal 2025, bringing in $5.10B of $10.27B (50%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch Lomb/ International | — | — | — | — | |||||||||||||
| Bausch Lomb/International | — | — | — | — | |||||||||||||
| Baush & Lomb/International | — | — | — | — | |||||||||||||
| Bausch + Lomb | $3.77B | $4.15B | $4.79B | $5.10B | |||||||||||||
| Developed Markets | — | — | — | — | |||||||||||||
| Branded Rx | — | — | — | — | |||||||||||||
| Salix | $2.09B | $2.25B | $2.33B | $2.58B | |||||||||||||
| U.S. Diversified Products | — | — | — | — | |||||||||||||
| Diversified Products | — | — | — | — | |||||||||||||
| International | $988.00M | $1.07B | $1.11B | $1.13B | |||||||||||||
| International Rx | — | — | — | — | |||||||||||||
| Diversified | $978.00M | $943.00M | $950.00M | $937.00M | |||||||||||||
| Emerging Markets | — | — | — | — | |||||||||||||
| Ortho Dermatologics | — | — | — | — | |||||||||||||
| Usneurology & Other | — | — | — | — | |||||||||||||
| Solta Medical | $300.00M | $347.00M | $440.00M | $518.00M | |||||||||||||
| Usdermatology | — | — | — | — | |||||||||||||
| Canada & Australia | — | — | — | — | |||||||||||||
| Branded Generics Europe | — | — | — | — | |||||||||||||
| Total | $8.12B | $8.76B | $9.63B | $10.27B |
Bausch Health Companies brought in $10.27B from its five segments in fiscal 2025, the year ended December 31, 2025. That was up 6.7% from $9.63B in fiscal 2024. Bausch + Lomb was the largest at $5.10B (49.7%), ahead of Salix at $2.58B (25.1%) and International at $1.13B (11.0%). The other two segments brought in $1.46B combined.
Compared with fiscal 2024, Solta Medical grew fastest, up 17.7% to $518.00M, while Diversified fell the most, down 1.4% to $937.00M. From fiscal 2022 to 2025, combined revenue from these segments grew from $8.12B to $10.27B, a compound annual growth rate of 8.1%. Bausch + Lomb's share of the total rose from 46.4% to 49.7%.
Pharmaceuticals was Bausch Health Companies’s largest product and service line in fiscal 2025, bringing in $4.75B of $10.27B (46%).
| Product and Service | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | $3.64B | $3.91B | $4.40B | $4.75B | |||||||||||
| Devices | $1.87B | $2.00B | $2.24B | $2.44B | |||||||||||
| Otc | $1.62B | $1.80B | $1.90B | $2.01B | |||||||||||
| Branded & Other Generics | $892.00M | $960.00M | $979.00M | $962.00M | |||||||||||
| Alliance & Royalty, Service And Other | — | — | — | — | |||||||||||
| Other Revenues | $99.00M | $94.00M | $107.00M | $110.00M | |||||||||||
| Total | $8.12B | $8.76B | $9.63B | $10.27B |
Bausch Health Companies brought in $10.27B from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 6.7% from $9.63B in fiscal 2024. Pharmaceuticals was the largest at $4.75B (46.2%), ahead of Devices at $2.44B (23.8%) and Otc at $2.01B (19.6%). The other two lines brought in $1.07B combined.
Compared with fiscal 2024, Devices grew fastest, up 8.9% to $2.44B, while Branded & Other Generics fell the most, down 1.7% to $962.00M. From fiscal 2022 to 2025, combined revenue from these lines grew from $8.12B to $10.27B, a compound annual growth rate of 8.1%. Pharmaceuticals' share of the total rose from 44.8% to 46.2%.
Bausch Health Companies (BHC) reports its revenue by geography, by segment and by product and service. In fiscal 2025, U.S was its largest region, bringing in $6.14B (59.8% of the total), followed by Other at $1.15B (11.2%).
U.S was Bausch Health Companies' largest region in fiscal 2025, bringing in $6.14B, or 59.8% of the $10.27B total across its 14 regions.
Bausch + Lomb was Bausch Health Companies' largest segment in fiscal 2025, bringing in $5.10B, or 49.7% of the $10.27B total across its five segments.
Pharmaceuticals was Bausch Health Companies' largest product and service line in fiscal 2025, bringing in $4.75B, or 46.2% of the $10.27B total across its five product and service lines.
Among Bausch Health Companies' regions that make up at least 2% of revenue, South Korea grew fastest in fiscal 2025, up 60.3% from $146.00M to $234.00M.
Every figure comes from Bausch Health Companies' annual financial filings, as reported. Each line keeps the name Bausch Health Companies gives it, and years follow its fiscal calendar.
Bausch Health Companies' revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.